6:08 PM
 | 
Oct 26, 2012
 |  BC Extra  |  Clinical News

Sandoz begins U.S. Phase III trial of biosimilar epoetin alfa

Novartis AG (NYSE:NVS; SIX:NOVN) said its Sandoz unit began a U.S. Phase III trial of a biosimilar version of anemia drug

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >